ATE245191T1 - Schweinecircoviren abgeleitete impfstoffe - Google Patents

Schweinecircoviren abgeleitete impfstoffe

Info

Publication number
ATE245191T1
ATE245191T1 AT98946547T AT98946547T ATE245191T1 AT E245191 T1 ATE245191 T1 AT E245191T1 AT 98946547 T AT98946547 T AT 98946547T AT 98946547 T AT98946547 T AT 98946547T AT E245191 T1 ATE245191 T1 AT E245191T1
Authority
AT
Austria
Prior art keywords
pcv
orfs
antigen
preparation
vector
Prior art date
Application number
AT98946547T
Other languages
English (en)
Inventor
Gordon Allan
Brian Meehan
Edward Clark
John Ellis
Deborah Haines
Lori Hassard
John Harding
Catherine Elisabeth Charreyre
Gilles Emile Chappuis
Francis Mcneilly
Original Assignee
Merial Sas
Univ Belfast
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27253376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE245191(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9712382A external-priority patent/FR2769321B1/fr
Priority claimed from FR9800873A external-priority patent/FR2769322B1/fr
Priority claimed from FR9803707A external-priority patent/FR2776294B1/fr
Application filed by Merial Sas, Univ Belfast, Univ Saskatchewan filed Critical Merial Sas
Application granted granted Critical
Publication of ATE245191T1 publication Critical patent/ATE245191T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
    • A23C19/0321—Propionic acid bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
    • A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • C12N2750/10064—Methods of inactivation or attenuation by serial passage

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT98946547T 1997-10-03 1998-10-01 Schweinecircoviren abgeleitete impfstoffe ATE245191T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9712382A FR2769321B1 (fr) 1997-10-03 1997-10-03 Nouveaux circovirus porcins, vaccins et reactifs de diagnostics
FR9800873A FR2769322B1 (fr) 1997-10-03 1998-01-22 Nouveaux circovirus porcins, vaccins et reactifs de diagnostic
FR9803707A FR2776294B1 (fr) 1998-03-20 1998-03-20 Nouveaux circovirus porcins ; vaccins et reactifs de diagnostic
PCT/FR1998/002107 WO1999018214A1 (fr) 1997-10-03 1998-10-01 Circovirus porcins, vaccins et reactifs de diagnostic

Publications (1)

Publication Number Publication Date
ATE245191T1 true ATE245191T1 (de) 2003-08-15

Family

ID=27253376

Family Applications (3)

Application Number Title Priority Date Filing Date
AT98946547T ATE245191T1 (de) 1997-10-03 1998-10-01 Schweinecircoviren abgeleitete impfstoffe
AT02017134T ATE299531T1 (de) 1997-10-03 1998-10-01 Schweinecircoviren
AT03016998T ATE387914T1 (de) 1997-10-03 1998-10-01 Verfahren zur in vitro-diagnose von infektionen durch schweinecircovirus vom typ ii und diagnostische reagenzien

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT02017134T ATE299531T1 (de) 1997-10-03 1998-10-01 Schweinecircoviren
AT03016998T ATE387914T1 (de) 1997-10-03 1998-10-01 Verfahren zur in vitro-diagnose von infektionen durch schweinecircovirus vom typ ii und diagnostische reagenzien

Country Status (20)

Country Link
US (1) US6368601B1 (de)
EP (4) EP1741785B1 (de)
JP (5) JP5008218B2 (de)
KR (4) KR100904852B1 (de)
CN (2) CN101724606B (de)
AT (3) ATE245191T1 (de)
AU (1) AU756554C (de)
BR (1) BR9812845B1 (de)
CA (1) CA2305623C (de)
CY (3) CY1110359T1 (de)
DE (7) DE05014998T1 (de)
DK (4) DK1281760T5 (de)
ES (4) ES2302885T3 (de)
FR (1) FR05C0021I2 (de)
HU (2) HU226247B1 (de)
NL (1) NL300326I2 (de)
PL (1) PL198506B1 (de)
PT (4) PT1281760E (de)
UA (1) UA78180C2 (de)
WO (1) WO1999018214A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
US7211379B2 (en) * 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US7192594B2 (en) * 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
EP1816200B1 (de) * 1997-12-11 2016-03-09 Merial Virus des multisystemischen Kümmersyndroms bei Absatzferkeln
NZ505008A (en) * 1997-12-11 2003-07-25 Univ Saskatchewan Porcine circovirus (PCV) isolates from pigs displaying postweaning multisystemic wasting syndrome virus
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
EP1290016A2 (de) * 2000-06-15 2003-03-12 Purdue Research Foundation Impfstoff gegen kongenitales tremor bei schweinen
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
KR100876629B1 (ko) 2001-03-27 2009-01-07 유니버시티 오브 사스카췌완 써코바이러스의 배양 방법
NZ531025A (en) 2001-07-20 2005-08-26 Univ Georgia Res Found Vaccine comprising a mutant rabies virus N protein which has an amino acid other than serine at position 389 and possibly one or more other mutations within the N protein
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
NZ538394A (en) * 2002-08-26 2008-06-30 Pfizer Prod Inc Vaccine for respiratory and reproductive system infections in cattles
KR20040021988A (ko) * 2002-09-06 2004-03-11 서상희 바이러스 증식용 돼지 신장 상피 세포주, 및 이의 용도
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
BRPI0607540B1 (pt) * 2005-04-13 2017-05-09 Merial Ltd ensaio para a produção de circovírus porcino
EP1792996A1 (de) * 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nukleinsäuren, kodierend für Impfstoffe gegen den reproduktiven und respiratorischen Syndrom Virus (prrsv)
US20080226669A1 (en) 2005-12-29 2008-09-18 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
PL2371383T3 (pl) 2005-12-29 2016-01-29 Boehringer Ingelheim Vetmedica Inc Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
KR100870077B1 (ko) * 2006-10-27 2008-11-25 권영득 이유후 전신소모성증후군(ｐｍｗｓ)의 치료용 복합제조성물
WO2008073464A2 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
ES2625460T5 (es) 2006-12-15 2020-11-04 Boehringer Ingelheim Animal Health Usa Inc Tratamiento de cerdos seropositivos en anticuerpo anti-PCV2 con antígeno de PCV2
EP1941903A1 (de) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxe und Behandlung von PRDC
EP1958644A1 (de) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Vorbeugung und Behandlung von subklinischer PCVD
RU2337690C1 (ru) * 2007-02-22 2008-11-10 Сергей Михайлович Юдин Способ экстренной неспецифической профилактики и лечения вирусных заболеваний свиней с синдромом pmws и парвовирусного энтерита плотоядных
US8518696B2 (en) * 2007-05-11 2013-08-27 Temasek Life Sciences Laboratory Limited Production of homogeneous cell line highly permissive to porcine circovirus type 2 (PCV2) infection
KR100948127B1 (ko) * 2007-06-27 2010-03-18 주식회사 중앙백신연구소 복합호흡기 질환 돼지의 조직유제를 함유하는 백신 조성물
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
EP2225367A1 (de) * 2007-12-21 2010-09-08 Wyeth LLC Verfahren und zusammensetzungen zur immunisierung von schweinen gegen porcines circovirus
BRPI0821456A2 (pt) * 2007-12-31 2015-06-16 Boehring Ingelheim Vetmedica Inc Partícula similar à pcv2 orf2 com inserção de aminoácido estranho
EP2242511A4 (de) 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed Immunogene pcv2-zusammensetzungen gegen mycoplasma hyopneumoniae und verfahren zur herstellung solcher zusammensetzungen
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
TWI442935B (zh) 2010-12-22 2014-07-01 Sbc Virbac Ltd 豬第二型環狀病毒（Ｐｏｒｃｉｎｅ Ｃｉｒｃｏｖｉｒｕｓ Ｔｙｐｅ ２）、含彼之免疫組合物、檢測套組及其應用
EP2564869A1 (de) 2011-09-02 2013-03-06 Ceva Sante Animale Synthetische Kapsidproteine und deren Verwendungen
EP2789346A1 (de) 2013-04-11 2014-10-15 CEVA Santé Animale SA Fusionspolypeptide und Impfstoffe
ES2882374T3 (es) 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
EP3049106A1 (de) 2013-09-25 2016-08-03 Zoetis Services LLC Divergente impfstoffzusammensetzung gegen pcv2b und verfahren zur verwendung
DK3052516T3 (da) 2013-10-02 2020-03-23 Boehringer Ingelheim Animal Health Usa Inc PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf
CN104383527A (zh) * 2014-11-18 2015-03-04 天津瑞普生物技术股份有限公司 一种猪圆环病毒2型灭活冻干疫苗的制备方法
EP3034609A1 (de) 2014-12-19 2016-06-22 Ceva Sante Animale Rekombinanter Schweinepockenvirus und Impfstoffe
EP3294876A1 (de) 2015-05-14 2018-03-21 Merial, Inc. Verfahren zur herstellung von porcinem circovirus und von pcv2-impfstoffen
EP3254692A1 (de) 2016-06-10 2017-12-13 Ceva Sante Animale Multivalente rekombinante spv
EP3720485A1 (de) 2017-12-08 2020-10-14 Ceva Sante Animale Rekombinanter schweinepockenvirus und impfstoffe
CN119488586A (zh) 2018-03-26 2025-02-21 勃林格殷格翰动物保健美国有限公司 制备免疫原性组合物的方法
BR112020025211A2 (pt) 2018-06-11 2021-03-09 Ceva Sante Animale Vacinação contra circovírus suíno
KR102124260B1 (ko) * 2018-10-19 2020-06-26 대한민국(관리부서 질병관리본부장) 신속 면역크로마토그래피법을 이용한 콜레라균 진단·탐지 키트 및 이를 위한 특이항체와 항체생산세포주
MX2023001024A (es) 2020-07-24 2023-02-15 Boehringer Ingelheim Animal Health Usa Inc Vacuna porcina combinada.
CN121463956A (zh) 2023-05-03 2026-02-03 勃林格殷格翰动物保健有限公司 诱导免疫应答的方法
AU2024266173A1 (en) 2023-05-03 2025-12-11 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for self-administration by pigs

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4740468A (en) 1985-02-14 1988-04-26 Syntex (U.S.A.) Inc. Concentrating immunochemical test device and method
US5232835A (en) 1986-11-07 1993-08-03 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
US5030558A (en) 1986-11-07 1991-07-09 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
CA1303983C (en) 1987-03-27 1992-06-23 Robert W. Rosenstein Solid phase assay
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US4855240A (en) 1987-05-13 1989-08-08 Becton Dickinson And Company Solid phase assay employing capillary flow
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
CA1332919C (en) * 1987-09-28 1994-11-08 Dale Bordt Viral vaccine
ATE240401T1 (de) 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
US5141850A (en) 1990-02-07 1992-08-25 Hygeia Sciences, Inc. Porous strip form assay device method
CA2082155C (en) 1990-05-29 2008-04-15 Krishnaswamy I. Dayalu Swine pneumonia vaccine and method of preparation
US5238652A (en) 1990-06-20 1993-08-24 Drug Screening Systems, Inc. Analytical test devices for competition assay for drugs of non-protein antigens using immunochromatographic techniques
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
US5266497A (en) 1990-08-31 1993-11-30 Japan Synthetic Rubber Co., Ltd. Immunochromatographic assay with improved colored latex
US5451504A (en) 1991-07-29 1995-09-19 Serex, Inc. Method and device for detecting the presence of analyte in a sample
ES2083764T5 (es) 1991-10-14 2009-04-01 Intervet International Bv Vacuna para el sindrome respiratorio reproductivo porcino (srrp) y diagnostico.
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
DE9204303U1 (de) 1992-03-30 1992-06-25 Marx, Günter Wolfgang, 7953 Bad Schussenried Trainingsgerät
EP0571648A1 (de) 1992-05-26 1993-12-01 Chung-Nan Weng Gegen mycoplasmale Lungenentzündung schützender Impfstoff
US6592873B1 (en) * 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
FR2700957B1 (fr) 1993-01-29 1995-03-03 Seppic Sa Composition de vaccin sous-unitaire recombinant vivant et procédé de préparation.
ES2152304T3 (es) 1993-02-08 2001-02-01 Bayer Ag Procedimiento para el crecimiento del virus del sindrome reproductivo y respiratorio porcino y su uso en vacunas.
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
EP1170368B1 (de) 1994-01-27 2010-07-28 University Of Massachusetts Medical Center Immunisierung durch Impfung von DNS Transkriptionseinheit
ATE206455T1 (de) * 1994-04-11 2001-10-15 Akzo Nobel Nv Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des schweins
AU7380494A (en) * 1994-08-05 1996-03-04 Karl P. Schneider Self-chamfering drill bit
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
NZ505008A (en) * 1997-12-11 2003-07-25 Univ Saskatchewan Porcine circovirus (PCV) isolates from pigs displaying postweaning multisystemic wasting syndrome virus
KR100298125B1 (ko) * 1999-04-15 2001-09-13 정명식 구리의 화학 증착에 유용한 유기 구리 전구체

Also Published As

Publication number Publication date
ES2246001T3 (es) 2006-02-01
EP1281760B1 (de) 2005-07-13
CY1115749T1 (el) 2017-01-25
CN101724606A (zh) 2010-06-09
JP2011135875A (ja) 2011-07-14
HUP0003756A3 (en) 2003-03-28
HU226247B1 (en) 2008-07-28
HU0800330D0 (en) 2008-07-28
CY1108113T1 (el) 2014-02-12
HK1095161A1 (en) 2007-04-27
DE69830858T4 (de) 2006-12-21
EP1386617B1 (de) 2008-03-05
EP1019510A1 (de) 2000-07-19
DK1281760T5 (da) 2006-04-18
AU756554B2 (en) 2003-01-16
ATE299531T1 (de) 2005-07-15
DK1281760T3 (da) 2005-10-31
DE69816460D1 (de) 2003-08-21
BR9812845A (pt) 2000-08-08
KR20010030930A (ko) 2001-04-16
DE122008000069I1 (de) 2009-11-05
KR20090051274A (ko) 2009-05-21
FR05C0021I1 (de) 2005-05-27
AU9355598A (en) 1999-04-27
PL339631A1 (en) 2001-01-02
PT1281760E (pt) 2005-11-30
CA2305623A1 (fr) 1999-04-15
BR9812845B1 (pt) 2010-03-09
CN101724606B (zh) 2016-02-24
KR20060079256A (ko) 2006-07-05
DK1019510T3 (da) 2003-11-10
EP1281760A1 (de) 2003-02-05
CN1278301A (zh) 2000-12-27
PL198506B1 (pl) 2008-06-30
HUP0003756A2 (hu) 2001-02-28
EP1386617A1 (de) 2004-02-04
PT1019510E (pt) 2003-11-28
ES2203984T3 (es) 2004-04-16
JP2001519159A (ja) 2001-10-23
AU756554C (en) 2003-09-18
KR100736129B1 (ko) 2007-07-06
DK1741785T3 (da) 2014-11-10
NL300326I1 (nl) 2008-03-03
EP1019510B1 (de) 2003-07-16
CA2305623C (en) 2008-04-01
DE05014998T1 (de) 2008-11-20
JP5869658B2 (ja) 2016-02-24
UA78180C2 (uk) 2007-03-15
ES2302885T3 (es) 2008-08-01
US6368601B1 (en) 2002-04-09
DE69830858T2 (de) 2006-04-20
DE69830858D1 (de) 2005-08-18
FR05C0021I2 (de) 2005-10-21
DE122005000009I1 (de) 2005-08-04
WO1999018214A1 (fr) 1999-04-15
JP2015109840A (ja) 2015-06-18
CN100584948C (zh) 2010-01-27
JP4680245B2 (ja) 2011-05-11
JP2012193179A (ja) 2012-10-11
ATE387914T1 (de) 2008-03-15
KR100854615B1 (ko) 2008-08-27
KR20080023271A (ko) 2008-03-12
DE69816460T2 (de) 2004-05-27
PT1386617E (pt) 2008-06-17
JP2008086317A (ja) 2008-04-17
JP5362750B2 (ja) 2013-12-11
JP5008218B2 (ja) 2012-08-22
EP1741785A1 (de) 2007-01-10
DE69839227D1 (de) 2008-04-17
ES2524359T3 (es) 2014-12-05
KR100904852B1 (ko) 2009-06-25
HU230340B1 (hu) 2016-02-29
CY1110359T1 (el) 2015-04-29
DK1386617T3 (da) 2008-07-07
KR100944144B1 (ko) 2010-02-24
EP1741785B1 (de) 2014-10-01
EP1281760B9 (de) 2005-12-28
PT1741785E (pt) 2014-11-13
DE69839227T2 (de) 2009-03-12
NL300326I2 (nl) 2008-04-01

Similar Documents

Publication Publication Date Title
ATE245191T1 (de) Schweinecircoviren abgeleitete impfstoffe
Guo et al. Expression and self-assembly in baculovirus of porcine enteric calicivirus capsids into virus-like particles and their use in an enzyme-linked immunosorbent assay for antibody detection in swine
EP2618841B1 (de) Bvdv-impfstoff
Bruschke et al. A subunit vaccine based on glycoprotein E2 of bovine virus diarrhea virus induces fetal protection in sheep against homologous challenge
ATE109512T1 (de) Expression und diagnose mit gag-kodierten peptiden, die mit antikörpern gegen lav immunologisch reaktiv sind.
RU2000111496A (ru) Новые цирковирусы свиней, вакцины и реагенты для диагностики
Li et al. A Semliki Forest virus replicon vectored DNA vaccine expressing the E2 glycoprotein of classical swine fever virus protects pigs from lethal challenge
Zelnik et al. An enzyme‐linked immunosorbent assay (ELISA) for detection of Marek's disease virus‐specific antibodies and its application in an experimental vaccine trial
Monteil et al. Effective priming of neonates born to immune dams against the immunogenic pseudorabies virus glycoprotein gD by replication-incompetent adenovirus-mediated gene transfer at birth
Hernández et al. Immunogenicity of a recombinant adenovirus expressing porcine reproductive and respiratory syndrome virus polyepitopes
Li et al. Co-expression of the C-terminal domain of Yersinia enterocolitica invasin enhances the efficacy of classical swine-fever-vectored vaccine based on human adenovirus
Sun et al. Comparison of the protective efficacy of recombinant adenoviruses against classical swine fever
Kaden et al. Oral vaccination against classical swine fever with a chimeric Pestivirus: comparative investigations of liquid and lyophilized virus
KR100785397B1 (ko) 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
TWI328039B (de)
TWI393778B (zh) Recombinant swine fever virus E2 glycoprotein, its single source antibody and its application in diagnostic reagents and subunit vaccines (2)
Ishii et al. Highly attenuated vaccinia virus DIs as a potential SARS vaccine
Egyed et al. Genomic and pathogenic studies on a glycoprotein E variant field isolate of bovine herpesvirus 1
Sharma et al. Expression and Immunogenicity of E2 Glycoprotein Gene of Classical Swine Fever Virus Cloned in Eukaryotic Expression Vector
Kumar et al. P. 354 HBV specific acyclic pyrimidine nucleosides: synthesis and anti-HBV activity of 5-and/or 6-substituted analogs of 1-[(2-hydroxyethoxy) methyl] uracils
Agrawal et al. P. 355 Dendritic cells expressing hepatitis C virus (HCV) derived antigens NS3 or Core: phenotype, antigen presentation and T cell stimulation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1019510

Country of ref document: EP